Atlas Venture Life Science Advisors LLC Sells 125,000 Shares of Disc Medicine, Inc. $IRON

Key Points

• Atlas Venture Life Science Advisors LLC reduced its stake in Disc Medicine, Inc. by 5.0%, selling 125,000 shares to hold approximately 2,384,456 shares, which now constitutes about 22.7% of its investment portfolio.
• CEO John D. Quisel sold 34,800 shares of Disc Medicine at an average price of $55.33, resulting in a total transaction of nearly $1.93 million, reducing his ownership by 17.70%.
• Disc Medicine's stock has a market cap of $2.10 billion and reported earnings per share of ($1.58), missing analysts' expectations, with an average target price set at $98.30 by Wall Street analysts.

Atlas Venture Life Science Advisors LLC decreased its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 5.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,384,456 shares of the company's stock after selling 125,000 shares during the period. Disc Medicine makes up approximately 22.7% of Atlas Venture Life Science Advisors LLC's holdings, making the stock its 2nd largest position. Atlas Venture Life Science Advisors LLC owned approximately 6.90% of Disc Medicine worth $118,364,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in IRON. Sterling Capital Management LLC boosted its stake in shares of Disc Medicine by 798.4% during the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock worth $36,000 after buying an additional 503 shares during the period. Amalgamated Bank boosted its stake in shares of Disc Medicine by 38.6% during the first quarter. Amalgamated Bank now owns 787 shares of the company's stock worth $39,000 after buying an additional 219 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Disc Medicine during the fourth quarter worth about $40,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Disc Medicine by 13,428.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 947 shares of the company's stock worth $47,000 after buying an additional 940 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after buying an additional 266 shares during the period. Institutional investors and hedge funds own 83.70% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IRON shares. Raymond James Financial began coverage on Disc Medicine in a research note on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 price target on the stock. Wedbush reissued an "outperform" rating and issued a $90.00 target price on shares of Disc Medicine in a research report on Monday, July 21st. HC Wainwright reaffirmed a "buy" rating and set a $118.00 price target on shares of Disc Medicine in a research report on Thursday, July 3rd. BMO Capital Markets raised their price objective on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research report on Monday, May 12th. Finally, Truist Financial began coverage on Disc Medicine in a research report on Monday, July 21st. They issued a "buy" rating and a $86.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $98.30.

Disc Medicine Stock Performance

Shares of IRON stock traded up $0.37 on Tuesday, hitting $59.78. 227,981 shares of the stock traded hands, compared to its average volume of 331,909. The company's fifty day moving average is $57.01 and its 200 day moving average is $51.66. Disc Medicine, Inc. has a 1-year low of $30.82 and a 1-year high of $68.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 32.11 and a current ratio of 32.11.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.41). As a group, research analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Disc Medicine news, CEO John D. Quisel sold 34,800 shares of the business's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $55.33, for a total transaction of $1,925,484.00. Following the sale, the chief executive officer directly owned 161,828 shares in the company, valued at approximately $8,953,943.24. The trade was a 17.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kevin Bitterman sold 2,287 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $61.03, for a total transaction of $139,575.61. Following the sale, the director owned 590,621 shares in the company, valued at $36,045,599.63. This trade represents a 0.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 135,909 shares of company stock worth $8,006,371 over the last quarter. 3.64% of the stock is owned by company insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.